3D bioprinting for cancer modeling and drug screening
Abstract
3D bioprinting has emerged as a promising preclinical technology to explore tumor cell biology, interaction with the microenvironment, and drug sensitivity. Current methods allow inclusion of several cell types within the bioprinted objects and may also be compatible with migration of immune cells within the object. 3D bioprinted tumor models have been shown to be more relevant for preclinical studies than classical 2D systems for a number of key parameters including cell morphology, cell-cell interactions, interaction with non-tumor cells, drug diffusion and sensitivity. As compared to other 3D models, bioprinting is applicable to a large variety of tumor cell lines at a relatively low cost and may be performed over a flexible period of time, ranging from a few days to several weeks. Bioprinting has also increasingly been applied to primary samples from cancer patients. In this review, we present the promises and technical hurdles yet to overcome in order for 3D bioprinting models to be fully exploited in preclinical modeling of cancer.
Related
- Fast computational screening of extrusion parameters for bioprinting of skeletal myoblasts in alginate hydrogel
- A Cell-based Screening Method Using an Intracellular Antibody for Discovering Small Molecules Targeting Hard-to-drug Proteins
- High-throughput platforms for genetic perturbation screening using CRISPR/Cas9 in human iPSC-derived macrophages for drug discovery
- Modeling of the human rhinovirus C capsid suggests possible causes for antiviral drug resistance
- Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)-related cirrhosis aware of their HCV status improves survival: A modeling approach
BibTeX
@article{cadiou2026bioprinting,
title = {{3D bioprinting for cancer modeling and drug screening}},
author = {Aurélie Cadiou and Eva-Laure Peiller Matera and Nicolas Ellinger and Lars Petter Jordheim and Michael Duruisseaux and Christophe Marquette and Charles Dumontet},
journal = {Biomarker Research},
year = {2026},
month = jun,
doi = {10.1186/s40364-026-00951-x},
url = {https://hal.science/hal-05761683v1},
note = {CC BY},
}
RIS
TY - JOUR
TI - 3D bioprinting for cancer modeling and drug screening
AU - Aurélie Cadiou
AU - Eva-Laure Peiller Matera
AU - Nicolas Ellinger
AU - Lars Petter Jordheim
AU - Michael Duruisseaux
AU - Christophe Marquette
AU - Charles Dumontet
PY - 2026
DA - 2026/06/20
JO - Biomarker Research
DO - 10.1186/s40364-026-00951-x
UR - https://hal.science/hal-05761683v1
AB - 3D bioprinting has emerged as a promising preclinical technology to explore tumor cell biology, interaction with the microenvironment, and drug sensitivity. Current methods allow inclusion of several cell types within the bioprinted objects and may also be compatible with migration of immune cells within the object. 3D bioprinted tumor models have been shown to be more relevant for preclinical studies than classical 2D systems for a number of key parameters including cell morphology, cell-cell interactions, interaction with non-tumor cells, drug diffusion and sensitivity. As compared to other 3D models, bioprinting is applicable to a large variety of tumor cell lines at a relatively low cost and may be performed over a flexible period of time, ranging from a few days to several weeks. Bioprinting has also increasingly been applied to primary samples from cancer patients. In this review, we present the promises and technical hurdles yet to overcome in order for 3D bioprinting models to be fully exploited in preclinical modeling of cancer.
SN - 2050-7771
ER -